Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alon Ben-Noon
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 1.58
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -101.05
Financials
Net Income
$-3.21MEBITDA
$-3.19M-22903.6%Free Cash Flow
$-1.84MEPS (diluted)
$-2.60Shares Outstanding (diluted)
1.28M+368.6%Operating Expenses
$3.20MCash & Debt
$166.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.13M | $-8.80 |
| 2024 | $0.00 | $-10.21M | $-11.00 |
| 2023 | $0.00 | $-10.11M | $-16.60 |
| 2022 | $0.00 | $-12.34M | $-21.40 |
| 2021 | $0.00 | $-4.04M | $-4.60 |
| 2020 | $0.00 | $-2.83M | $-10.20 |
| 2019 | $0.00 | $-1.23M | $-4.40 |
Valuation
NRSNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsprnewswire.com·7d ago·Neutral
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one investor meetings during the conference CAMBRIDGE, Mass., Sept. 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·10d ago·Neutral
NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.
View source ↗ - Newsprnewswire.com·36d ago·Neutral
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mas
View source ↗ - Newsprnewswire.com·53d ago·Neutral
NeuroSense Issues CEO Letter to Shareholders CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
View source ↗
Earnings
Typical surprise +19.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 25$-2.06 vs $-3.90beat
- Tue, Jun 30$-3.90 vs $-3.90beat
- Tue, Mar 31$-0.23 vs $-0.07miss
- Wed, Dec 17$-2.60 vs $-0.87miss
- Fri, Aug 1$-0.14 vs $-0.22beat
- Mon, Apr 7$-0.06 vs $-0.10beat
Estimates and results for NRSN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRSN officers and directors.
- Bought
- $400k
- Sold
- —
2 trades
0 trades
- Ben-noon Alonbought
- Eisenberg Orbought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRSN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.